Pulmonx opened lower at $2.95, compared with its previous close of $2.98. In the last trading session, the stock traded between $2.88 and $3.17. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Pulmonx is now worth
$ 7.21
Resulting in a loss of
$ 92.79 (92.79%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
66.67%
Hold
33.33%
Sell
0%
Markets Today
Today's Change
+$0.03 (+0.91%)
Day High
$3.17
Day Low
$2.88
Day Open
$2.95
Prev Close
$2.98
Volume
10,02,675
1W Return
6.44%
1M Return
67.33%
3M Return
32.70%
6M Return
131.31%
1Y Return
43.88%
Fundamentals
Market Cap ($ Mn)
131
PE Ratio
-
PB Ratio
2.61
PEG Ratio
-
ROE
-77.88%
ROCE
-43.09%
EPS (TTM)
$-0.19
Investment Returns
1 Week
6.44%
1 Month
67.33%
3 Months
32.70%
6 Months
131.31%
9 Months
107.38%
Financials
Quarterly
All values in $ Mn
23.9
Jun 25
21.5
Sep 25
22.6
Dec 25
20.6
Mar 26
22.8
Jun 26
22.8
Sep 26
Updates
14Oct
Pulmonx to report Q3FY26 results on October 27
Pulmonx will release Q3 2026 financial results on October 27, 2026. Conference call scheduled for 4:30 pm ET following the announcement. Webcast available via the company's investor relations website.
1mo ago
28Aug
Pulmonx to hold investor meetings at Wells Fargo, Lake Street conferences
Pulmonx management to hold 1x1 investor meetings in September. Wells Fargo Healthcare Conference participation set for Sept 9 in Boston. Lake Street Best Ideas Growth Conference appearance on Sept 10 in New York. Company focuses on minimally invasive COPD treatments including Zephyr Valve.
2mo ago
30Jul
Pulmonx Affirms FY26 Sales Guidance of $90.000M-$92.000M
Pulmonx reaffirms its FY2026 sales guidance of $90.000M-$92.000M, matching prior expectations and aligning with the $90.832M analyst estimate. The stability in outlook reflects consistent operational performance and market consensus.
3mo ago
29Jul
Pulmonx to present at Canaccord Genuity 46th Annual Growth Conference
Pulmonx Corporation will hold a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. The event will be webcast live from Boston. Pulmonx remains a leader in minimally invasive COPD treatments, with its Zephyr Valve available in over 25 countries.
3mo ago
16Jul
Pulmonx to report Q2 2026 financial results on July 29
Pulmonx Corporation will announce its Q2 2026 financial results on July 29, 2026, followed by a conference call at 1:30 p.m. PT. The company specializes in minimally invasive treatments for COPD, with products like the Zephyr Valve available in over 25 countries.
